These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 16919087)
21. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. Soriano V; Labarga P; Ruiz-Sancho A; Garcia-Samaniego J; Barreiro P AIDS; 2006 Nov; 20(17):2225-7. PubMed ID: 17086063 [No Abstract] [Full Text] [Related]
22. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection]. Lee MY; Cho H; Kim YM; Lee JS Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297 [TBL] [Abstract][Full Text] [Related]
23. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Behler CM; Vittinghoff E; Lin F; Chung RT; Peters MG; Robbins GK; Volberding PA Clin Infect Dis; 2007 May; 44(10):1375-83. PubMed ID: 17443478 [TBL] [Abstract][Full Text] [Related]
24. T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective antiretroviral therapy. Arizcorreta A; Márquez M; Fernández-Gutiérrez C; Guzmán EP; Brun F; Rodríguez-Iglesias M; Girón-González JA Clin Exp Immunol; 2006 Nov; 146(2):270-7. PubMed ID: 17034579 [TBL] [Abstract][Full Text] [Related]
25. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment. Berk SI; Litwin AH; Arnsten JH; Du E; Soloway I; Gourevitch MN Clin Ther; 2007 Jan; 29(1):131-8. PubMed ID: 17379053 [TBL] [Abstract][Full Text] [Related]
26. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK; J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184 [TBL] [Abstract][Full Text] [Related]
27. [Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response]. Zeuzem S MMW Fortschr Med; 2002 Feb; 144(8):30-4. PubMed ID: 11910820 [TBL] [Abstract][Full Text] [Related]
28. Peginterferon and ribavirin for hepatitis C. Ben Salem C; Hmouda H; Bouraoui K N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380578 [No Abstract] [Full Text] [Related]
29. [Progress in the treatment of hepatitis B and C co-infection in HIV patients]. Mauss S MMW Fortschr Med; 2004 Apr; 146 Spec No 1():27-9. PubMed ID: 15373041 [TBL] [Abstract][Full Text] [Related]
30. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon. Veldt BJ; Schalm SW; Janssen HL J Clin Gastroenterol; 2007 Apr; 41(4):432. PubMed ID: 17413616 [No Abstract] [Full Text] [Related]
31. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin. Demirturk N; Aykin N; Demirdal T; Cevik F Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483 [No Abstract] [Full Text] [Related]
32. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815 [TBL] [Abstract][Full Text] [Related]
33. Pulmonary complications associated with pegylated interferon and ribavirin in HIV/hepatitis C virus coinfected patients. Vasilij Benatti S; Giampaolo Q; Sara B; Marco R; Diego R AIDS; 2014 Nov; 28(17):2633-5. PubMed ID: 25574965 [No Abstract] [Full Text] [Related]
34. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C]. Enjoji M; Dainichi T; Gondo H; Urabe K Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079 [TBL] [Abstract][Full Text] [Related]
35. Acquired haemophilia A in a patient with chronic hepatitis C virus infection receiving treatment with pegylated interferon plus ribarivin: role of rituximab. Fernández de Palencia Espinosa MÁ; Arocas Casañ V; Garrido Corro B; de la Rubia Nieto A Farm Hosp; 2013; 37(6):494-8. PubMed ID: 24256012 [TBL] [Abstract][Full Text] [Related]
36. [Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients]. Montes-Ramírez ML; Rodríguez-Zapata M Enferm Infecc Microbiol Clin; 2006 Mar; 24(3):213-4. PubMed ID: 16606567 [No Abstract] [Full Text] [Related]
37. [Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report]. Bassetti BR; Trés ES; Ciríaco JG; Pinto Neto LF Rev Soc Bras Med Trop; 2010; 43(1):89-91. PubMed ID: 20305976 [TBL] [Abstract][Full Text] [Related]
38. Association of pancreatic autoantibodies and human leukocyte antigen haplotypes with resolution of diabetes mellitus after therapy for hepatitis C virus infection in patients with HIV infection: case report and review of literature. Lo YC; Chang SY; Sheng WH; Hung CC; Chang SC Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):478-81. PubMed ID: 19369830 [TBL] [Abstract][Full Text] [Related]
39. Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. Vispo E; Maida I; Moreno A; Barreiro P; Soriano V J Antimicrob Chemother; 2008 Dec; 62(6):1470-2. PubMed ID: 18835807 [No Abstract] [Full Text] [Related]
40. Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. Ramos B; Sheldon J; Ruiz-Sancho A; Toro C; Ríos P; Soriano V AIDS; 2007 Mar; 21(5):652-3. PubMed ID: 17314531 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]